Novartis Reports Phase 2 GEOMETRY Mono-1 Trial Of Investigational INC280 Showed 'overall response rate of 72%, 39.1%, respectively, in treatment-naive, previously treated patients with advanced MET exon-14 skipping mutated non-small cell lung cancer'